Clinical Trial Update: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Update on AK104, a PD-1/CTLA-4 bispecific antibody, evaluated in Phase 1/2 for advanced solid tumors and as first-line therapy with mXELOX/XELOX for advanced ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Gastric Adenocarcinoma, Advanced Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED